Literature DB >> 24690015

Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis.

Zaid Zoumot1, Afroditi K Boutou, Simon S Gill, Mafalda van Zeller, David M Hansell, Athol U Wells, Robert Wilson, Michael R Loebinger.   

Abstract

BACKGROUND AND
OBJECTIVE: Reliable markers of disease progression or stability to assist in management decisions are lacking in patients with non-cystic fibrosis bronchiectasis and Mycobacterium avium complex (MAC) infection.
METHODS: Data from 52 adults with non-cystic fibrosis bronchiectasis and coexisting MAC infection managed at our institution over a 5-year period were retrospectively analysed. High-resolution computed tomography (HRCT) scans were scored using a scoring system that focused on findings associated with MAC infection.
RESULTS: Chronic pulmonary aspergillosis was independently associated with mortality (hazard ratio (HR) = 8.916, 95% confidence interval (CI) = 1.324-60.027), as were nodules with cavitation (HR = 5.911, 95% CI = 1.095-25.911) and emphysema (HR = 1.027, 95% CI = 1.002-1.053) on HRCT. Anti-MAC chemotherapy was more likely to lead to MAC culture conversion (67% vs. 27%, P = 0.005) but did not improve survival as compared with patients managed with observation. Longitudinally, patients who had improvements in HRCT scores were younger (60.2 ± 9.19 years vs. 69.83 ± 12.43 years, P = 0.043), while the presence of cavitation within nodules predicted a deterioration in HRCT scores (0.5 (0-3) vs. 0 (0-1), P = 0.033). No significant longitudinal differences were found in lung function in the cohort as a whole or within different groups.
CONCLUSIONS: Chronic pulmonary aspergillosis in patients with bronchiectasis and coexisting MAC infection is a strong predictor of mortality. Cavitation within nodules and emphysema on HRCT at presentation were independently associated with mortality.
© 2014 Asian Pacific Society of Respirology.

Entities:  

Keywords:  aspergillus lung disease; atypical mycobacterial disease; bronchiectasis; respiratory infection (non-tuberculous)

Mesh:

Year:  2014        PMID: 24690015     DOI: 10.1111/resp.12287

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  21 in total

1.  Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.

Authors:  Seong Mi Moon; Hye Yun Park; Byeong-Ho Jeong; Kyeongman Jeon; Soo-Youn Lee; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

2.  Whole-Blood Gene Expression in Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Steven A Cowman; Joseph Jacob; David M Hansell; Peter Kelleher; Robert Wilson; William O C Cookson; Miriam F Moffatt; Michael R Loebinger
Journal:  Am J Respir Cell Mol Biol       Date:  2018-04       Impact factor: 6.914

3.  Clinical significance of Aspergillus species isolated from respiratory specimens in patients with Mycobacterium avium complex lung disease.

Authors:  K Furuuchi; A Ito; T Hashimoto; S Kumagai; T Ishida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-17       Impact factor: 3.267

Review 4.  Chronic Aspergillosis of the Lungs: Unravelling the Terminology and Radiology.

Authors:  S R Desai; V Hedayati; K Patel; D M Hansell
Journal:  Eur Radiol       Date:  2015-03-20       Impact factor: 5.315

5.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

6.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

Review 7.  Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis.

Authors:  Giulia Bonaiti; Alberto Pesci; Almerico Marruchella; Giuseppe Lapadula; Andrea Gori; Stefano Aliberti
Journal:  Biomed Res Int       Date:  2015-05-27       Impact factor: 3.411

8.  Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis.

Authors:  Paola Faverio; Anna Stainer; Giulia Bonaiti; Stefano C Zucchetti; Edoardo Simonetta; Giuseppe Lapadula; Almerico Marruchella; Andrea Gori; Francesco Blasi; Luigi Codecasa; Alberto Pesci; James D Chalmers; Michael R Loebinger; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2016-11-16       Impact factor: 5.923

Review 9.  Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis.

Authors:  Ravishankar Chandrasekaran; Micheál Mac Aogáin; James D Chalmers; Stuart J Elborn; Sanjay H Chotirmall
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

10.  Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease.

Authors:  Byung Woo Jhun; Woo Jin Jung; Na Young Hwang; Hye Yun Park; Kyeongman Jeon; Eun-Suk Kang; Won-Jung Koh
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.